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Abstract
Background & Aims: CCL25/CCR9 is a non-promiscuous chemokine/receptor pair and a key regulator of leukocyte
migration to the small intestine. We investigated here whether CCL25/CCR9 interactions also play a role in the regulation of
inflammatory responses in the large intestine.
Methods: Acute inflammation and recovery in wild-type (WT) and CCR9
2/2 mice was studied in a model of dextran sulfate
sodium (DSS)-induced colitis. Distribution studies and phenotypic characterization of dendritic cell subsets and macrophage
were performed by flow cytometry. Inflammatory bowel disease (IBD) scores were assessed and expression of inflammatory
cytokines was studied at the mRNA and the protein level.
Results: CCL25 and CCR9 are both expressed in the large intestine and are upregulated during DSS colitis. CCR9
2/2 mice are
more susceptible to DSS colitis than WT littermate controls as shown by higher mortality, increased IBD score and delayed
recovery. During recovery, the CCR9
2/2 colonic mucosa is characterized by the accumulation of activated macrophages and
elevated levels of Th1/Th17 inflammatory cytokines. Activated plasmacytoid dendritic cells (DCs) accumulate in mesenteric
lymph nodes (MLNs) of CCR9
2/2 animals, altering the local ratio of DC subsets. Upon re-stimulation, T cells isolated from
these MLNs secrete significantly higher levels of TNFa, IFNc, IL2, IL-6 and IL-17A while down modulating IL-10 production.
Conclusions: Our results demonstrate that CCL25/CCR9 interactions regulate inflammatory immune responses in the large
intestinal mucosa by balancing different subsets of dendritic cells. These findings have important implications for the use of
CCR9-inhibitors in therapy of human IBD as they indicate a potential risk for patients with large intestinal inflammation.
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Introduction
Crohn’s disease and ulcerative colitis represent two clinical
subtypes of inflammatory bowel disease (IBD). Infiltration of
inflammatory leukocytes into the gastrointestinal mucosa critically
regulates development as well as progression of both types of IBD.
Tissue- and cell type-specific leukocyte trafficking is orchestrated
by chemokines and their receptors. Interaction of CCL25 with
CCR9 identifies one of the few non-promiscuous chemokine/
receptor pairs involved in gut-specific migration of leukocytes.
CCL25 is strongly expressed by the small intestinal epithelium
[1,2,3] and regulates trafficking of gut-specific memory/effector T
cells via upregulation of the integrin homing receptor a4b7 and
CCR9 [4,5,6,7]. The chemokine itself is dispensable for the
development of CCR9
high intestinal memory-phenotype T cells.
CCX282-B (Traficet-EN, ChemoCentryx) is a small molecule that
can antagonize CCR9 function and has already shown promising
results in a phase II clinical trial of moderate to severe Crohn’s
Disease patients as it successfully delays disease progression [8]. As
CCL25/CCR9 interactions are currently considered dispensable
for the regulation of inflammation in the large intestine, the
therapeutic effect of the CCR9-antagonist has not been studied in
ulcerative colitis.
Several different murine models have been described to study
the pathophysiology of ulcerative colitis [9]. Administration of
Dextran Sulfate Sodium (DSS) in drinking water induces a
reversible form of colitis in mice [10]. This model is characterized
by acute tissue inflammation in the colon and mimics the
pathology of human ulcerative colitis. Since immuno-compro-
mised mice such as Recombinase-Activating Gene (RAG) deficient
mice or severe combined immune deficiency (SCID) mice lacking
the T and B cell compartment remain susceptible in this disease
model [11], a central role for monocytes/macrophages (MW) and
dendritic cells (DCs) was proposed for the pathogenesis of DSS
colitis and likewise for human ulcerative colitis. Consequently,
inflammatory MW were described as antigen-presenting cells
(APCs) that activate T cells and induce T cell proliferation in DSS
colitis [12,13].
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propria (LP), Peyer’s patches (PPs) and mesenteric lymph nodes
(MLN) and are the first APCs to sense and respond to exogenous
antigens or tissue injury [14]. Several subpopulations of DCs and
MW have been described in the intestinal microenvironment
[15,16,17]. Their respective functions for the induction of
protective immunity versus immune tolerance in the gut remain
poorly understood [14]. Recent studies have shown that depletion
of DCs during DSS-induced colitis leads to ameliorated or
exacerbated symptoms depending on the time point of interven-
tion [18,19,20]. These observations imply that concerted traffick-
ing of different DC subsets is critical for onset and recovery of
colitis. CCR9 is a candidate chemokine receptor for the regulation
of this type of DC trafficking, because it has been demonstrated
that CD11c-positive splenic DCs as well as peritoneal MW migrate
towards a CCL25 chemotactic gradient [1]. However the role of
CCL25/CCR9 interactions during the regulation of large
intestinal inflammation has not been studied so far.
Here we describe a so far unanticipated role of CCL25 and
CCR9 in the regulation of large intestinal inflammation. We show
that CCR9
2/2 animals display exacerbated colitis. In the absence
of physiological CCL25/CCR9 interactions, we detect an
imbalance of DC subpopulations and the accumulation of
inflammatory MW in the lamina propria of the colon and in
gut-associated lymphoid tissue.
Materials and Methods
Mice
The generation of CCR9
2/2 and CCL25
2/2 mice has been
described previously [7,21]. All strains of mice, including C57Bl/6
control mice were bred in the animal facility at Children’s Hospital
Boston, born and held in the same room under specific pathogen-
free conditions. To avoid variations of commensal bacteria in our
experiments, littermate controls were used. All animal experiments
were approved under animal protocol number 09-03-1326 by
Children’s Hospital Boston Institutional Animal Care and Use Committee.
Children’s Hospital Boston’s assurance number is A3303-01. Children’s
Hospital Boston is accredited by AAALAC International. All
efforts were made to minimize suffering of animals.
Dextran Sulfate Sodium- (DSS) mediated colitis
Sex- and age-matched mice received 2% DSS (36–50 kDa, MP
Biomedicals, LCC, Solon, OH) in the drinking water for 7 days
followed by 10-day water administration. The animal weight was
recorded daily. For flow cytometry, histology and mRNA analysis,
mice were euthanized at indicated time points, with day 0 (d0)
corresponding to the initiation of DSS treatment. All efforts were
made to minimize suffering of animals.
Preparation of cell suspensions
Spleens (SPL) and mesenteric lymph nodes (MLN) were
harvested in HBSS with Ca
2+ and Mg
2+ supplemented with 2%
fetal calf serum (FCS) and 10mM HEPES. SPL and MLN
suspensions were obtained by collagenase VIII digestion (Sigma-
Aldrich, St. Louis, MO) for 30 min at 37uC. Lamina Propria
Lymphocyte (LPL) suspensions were obtained as previously
described [7]. Large intestines were flushed and opened
longitudinally. To remove intra-epithelial lymphocytes and
epithelial cells, intestinal pieces were incubated in HBSS without
Ca
2+/Mg
2+ supplemented with 10mM EDTA, 10mM HEPES,
0.5% FCS and 1.5 mM DTET, for 2620 min at 37uC. Intestinal
pieces were digested in HBSS with Ca
2+/Mg
2+, 20% FCS,
100 U/ml collagenase VIII and 5 mg/ml DNase (Sigma-Aldrich)
for 60–90 min at 37uC. LPL were purified over a 40%–100%
Percoll gradient (GE Healthcare Bio-Sciences Corp, Piscataway,
NJ).
Flow Cytometry Analysis
Cell suspensions from SPL, MLN and large intestinal LP were
analyzed by flow cytometry. Cells were stained with FITC-, PE-,
PerCP-Cy5.5, PE-Cy7-, APC- or AF-647, APC-Cy7- or APC-
eF780-labeled mAbs for MHC II, CD11c, CD11b, Ly6C, PDCA-
1, CD103, CD8a, B220, CD19 (BD Biosciences, Franklin Lakes,
NJ), CCR9 (eBioscience, San Diego, CA), DX5 and CD3e
(Biolegend, San Diego, CA). Blocking of FccR-binding was
performed using mouse and rat serum (Jackson Immunoresearch,
West Grove, PA). Cells were analyzed on a FACS Canto II (BD
Biosciences, Franklin Lakes, NJ). Data were collected using FACS
Diva software (BD Biosciences) and analyzed with FlowJo software
(TreeStar, Ashland, OR).
Histology and IBD scoring
Intestinal samples of the distal colon were harvested, fixed in
10% formalin and embedded in paraffin for H&E staining.
Histological IBD scoring was performed blindly by a pathologist as
follows: IBD scores corresponding to 0=normal, 1=mild,
2=moderate, 3=severe were attributed to activity grade, changes
of crypt architecture, basal lymphoplasmacytosis, expansion of
lamina propria and epithelial hyperplasia. Scores were graphed in
a total range of 0–15.
mRNA quantification
Total RNA was extracted with TRIzol
TM (Invitrogen, Carlsbad,
CA) according to the manufacturer’s guidelines. Quantification of
total RNA was performed with a Nanodrop
TM spectrophotometer
(Thermo Scientific). For real-time RT-PCR, cDNA was synthe-
sized with iScript
TM Select cDNA Synthesis kit (Biorad, Hercules,
CA). Amplification was performed with the iQ5 quantitative PCR
System (Biorad) and iQ
TM SYBRH Green Supermix (Biorad) on
50ng RNA. CCR9 and CCL25 mRNAs were quantified using b-
actin mRNA for normalization. Primer sequences: CCL25
Forward: 59-ccaaggtgcctttgaagact-39, CCL25 Reverse: 59-
tcctccagctggtggttact-39, CCR9 Forward: 59-ccaggaaatctctggtctgc-
39, CCR9 Reverse: 59-ctgtggaagcagtggagtca, b-actin Forward: 59-
gctgtattcccctccatcgt -39, b-actin Reverse: 59-gccatgttcaatggggtact -
59. For nCounter
TM analysis (Nanostring, Seattle, WA), code sets
were generated by the GeneSelector algorithm [22]. 250 ng of
colonic RNA were hybridized for 16 h, loaded onto the
nCounter
TM prep-station and quantified with the nCounter
TM
Digital Analyzer. nCounter data were normalized in two steps
according to the manufacturer. We controlled for variations in the
efficiency of processing with controls from the manufacturer. Data
were normalized to Tomm7, Shfm1, Hprt1, Hsp90ab1 and actb
as housekeeping genes.
Cell culture and cytokine measurement
RPMI 1640 medium (GIBCO) supplemented with 10% FCS,
2 mmol/L L-glutamine, 100 U/ml penicillin-streptomycin, and
50 mmol/L 2-mercaptoethanol (Invitrogen) was used for all
cultures. 10
6 cells from WT and CCR9
2/2 MLN harvested at
d17 of DSS colitis were activated with immobilized anti-CD3 mAb
(145-2C11; 0.5 mg/ml) and soluble anti-CD28 mAb (BD Biosci-
ences). Supernatants were harvested at 72 h for cytokine
measurement by BD Cytometric Bead Array (CBA) using a
mouse Th1/Th2/Th17 kit according to the manufacturer’s
guidelines (BD Biosciences). Samples were analyzed on a FACS
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Biosciences) with FCAP Array Software (BD Biosciences).
Enrichment of pDCs
pDCs were enriched by positive selection with PDCA-1
conjugated magnetic beads (Miltenyi Biotec, Auburn, CA)
according to manufacturer. Purity was determined by flow
cytometry using mAbs anti-MHC II, CD11c, PDCA-1 and
B220 and Ly6C. Enrichment led to 90% purity.
Statistical Analysis
Weight loss, Colon length, IBD Scoring and cellular distribu-
tions were compared using either Student t-test or ANOVA test.
Differences with p,0.05 were considered significant. Statistical
analysis was performed using Prism (Graph Pad Software, La
Jolla, CA). Kaplan-Meier survival curves to DSS-mediated colitis
were created using Prism (Graph Pad Software).
Results
CCR9 and CCL25 are expressed in the mucosa of the
large intestine
In line with the literature [1,2,3], high levels of CCR9 and
CCL25 transcripts were detected in Peyer’s Patches (PPs) and in
the small intestine (SI). We found low-level expression of CCR9
and CCL25 in the large intestine (LI) of healthy wild-type (WT)
mice. Intestinal tissue from CCR9
2/2 and CCL25
2/2 animals
was used as a specificity control (Figure 1A).
We next analyzed whether large intestinal inflammation affects
expression levels of CCL25. Acute experimental colitis was
induced by addition of DSS in the drinking water for seven days
followed by a ten-day recovery period (Figure 1B). CCL25 mRNA
levels did not change significantly until day 10 (d10). At d13 and at
d17, CCL25 transcripts were significantly upregulated (6.9+/24.8
and 21.5+/211.2 fold induction, Figure 1C). Our data show that
CCL25 expression increases during DSS colitis, suggesting a
Figure 1. Expression of CCR9 and CCL25 in the large intestine. (A) Quantification of CCR9 and CCL25 mRNA levels from intestinal tissues of
WT, CCR9
2/2 and CCL25
2/2 mice. Y-axis shows expression levels normalized to b-actin mRNA (mean +/2 SD, n=3). PP: Peyer’s Patches, SI: Small
intestine, LI: Large intestine. Data represent the mean +/2 SD of 3 independent experiments, performed in triplicate (B) Acute DSS-mediated colitis.
Induction phase: 2% DSS in drinking water for 7 days. Recovery: 10 days water. Mice were analyzed at days 0 (d0), d7, d10, d13 and d17. (C) CCL25
mRNA expression increases during the recovery phase of DSS-mediated colitis, (mean +/2 SD; d0, n=3; d10, n=3; d13, n=5; d17, n=5; where n
corresponds to a single experiments of 3 to 5 pooled intestinal samples).
doi:10.1371/journal.pone.0016442.g001
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intestinal inflammation.
CCR9
2/2 mice show increased susceptibility to acute DSS
colitis
DSS colitis is dependent on the duration and dose of DSS
administration as well as the genetic background of the animals
[10,23,24]. We next compared the susceptibility of CCR9
2/2 and
WT mice to 3% DSS, as commonly used in C57Bl/6 mice.
Surprisingly, administration of this DSS concentration induced a
mortality of 100% in CCR9
2/2 animals during the recovery
phase (data not shown). We thus decreased the DSS concentration
to 2% resulting in a reduction of mortality to 30.65% (Figure 2A).
Both strains were susceptible to DSS colitis as evidenced by body
weight loss (Figure 2B). Maximal weight loss occurred in WT mice
by d10 and in CCR9
2/2 mice by d12. CCR9
2/2 mice lost
significantly more weight than WT animals. In contrast to WT
mice, CCR9
2/2 animals were unable to regain their initial body
weight during the water administration phase (Figure 2B). Like
CCR9
2/2 animals, CCL25
2/2 mice were more susceptible to
DSS colitis (Figure S1). Since similar results were obtained with
the CCL25
2/2 strain, these data show that the exacerbated colitis
is a consequence of impaired CCL25/CCR9 interaction.
Exacerbated IBD symptoms in CCR9
2/2 animals
We next analyzed how the increased susceptibility to DSS colitis
affects IBD symptoms in CCR9
2/2 animals. According to the
weight loss data in WT animals, IBD scoring of H&E sections of
the distal colon peaked at d10 and reversed during water
administration by d13. In contrast, CCR9
2/2 mice showed
persistent intestinal inflammation until d17 (Figure 3A and Table
S1). Intestinal inflammation in CCR9
2/2 mice was characterized
by an increase of cellular activity with granulocytic infiltration,
expansion of the lamina propria and more pronounced basal
lymphoplasmacytosis (Figure 3B). Epithelial hyperplasia, frequent
crypt abscesses and mucosal ulceration also persisted until d17
(Figure 3B). As opposed to WT animals, CCR9
2/2 mice still
showed shortening of the colon at the end of the DSS cycle
(Figure 3C and Table S2). CCL25 transcripts levels were not
upregulated in CCR9
2/2 large intestinal mucosa (Figure S2),
probably due to the altered ratio of infiltrating cells to resident cells
when compared to WT mucosa at the same time point (Figure S2).
In summary, these experiments describe exacerbated IBD
symptoms in the absence of CCR9 expression.
The gut-associated lymphoid tissue and the intestinal
mucosa of CCR9
2/2 mice show multiple signs of
exacerbated inflammation after DSS colitis
As recruitment and activation of intestinal MW has been
described in human ulcerative colitis and murine DSS colitis
[10,17], we analyzed the numbers and phenotype of MW in gut-
associated lymphoid tissue and intestinal mucosa. The cellularity
of lymphoid organs during DSS colitis was similar in WT and
CCR9
2/2 animals (Figure S3). At d17, however, a 3-fold increase
of MW was detected in MLNs of CCR9
2/2 animals compared to
WT mice. MW in both strains expressed the surface markers F4/
80 and Ly6C, suggesting an inflammatory phenotype [15]
(Figure 4A). CCR9
2/2 MW expressed higher levels of MHC II
than WT cells, indicating that these MW are more activated [25].
We next compared mRNA expression patterns of the large
intestinal tissue of WT and CCR9
2/2 animals at steady state and
at d17 using nCounter
TM mRNA analysis. This digital method-
ology allows for a direct analysis of mRNA copy numbers without
amplification steps [22]. In line with our flow cytometry analysis,
the increase in inflammatory MW at d17 was reflected by increased
expression of CD64 and Arginase1 (Figure 4B). As a reflection of
recent tissue inflammation, mRNA levels of TNFa, IL-1b and IL-
6 were increased at d17 (Figure 4C). CCR9
2/2 animals
consistently showed increased levels of all transcripts when
compared to WT (Figures 4B and 4C). Exacerbated IBD in
CCR9
2/2 mice further correlated with upregulation of IFNc, IL-
17A and IL-17F. No induction of IL-4 mRNA was observed
(Figure 4C).
We next studied cytokine production of T cells isolated from
MLNs at d17 after stimulation with anti-CD3e/CD28 mAbs
(Figure 4D and 4E). T cells from CCR9
2/2 animals produced
higher levels of TNFa, IFNc, IL-2, IL-6 and IL-17A than WT
cells. Production of IL-4 and IL-10 was significantly down-
regulated in CCR9
2/2 mice. In summary, this set of data
describes an exacerbated inflammatory immune response of the
Th1/Th17 immunophenotype with higher numbers of tissue
macrophages in the large intestinal mucosa and gut-associated
lymphoid tissues of CCR9
2/2 mice.
Figure 2. CCR9
2/2 mice show increased mortality and delayed
recovery during DSS-mediated colitis. (A) 30.65% mortality was
observed in CCR9
2/2 mice (open circles, n=78). WT mice are shown in
gray circles (n=66). Data are representative of 17 pooled experiments.
(B) CCR9
2/2 mice showed a more pronounced body weight loss than
WT. Body weight was monitored daily and is expressed as percent of
weight at d0 (data represent the mean +/2 SD of 17 pooled
experiments of 3–5 mice per group). Open circles show CCR9
2/2 mice,
gray circles WT.
doi:10.1371/journal.pone.0016442.g002
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of activated plasmacytoid DCs in MLNs
DCs aregatekeepersfor the induction ofadaptiveimmune responses
and different DC subpopulations are also considered key regulators of
inflammatory immune responses [14]. In particular, expression of
CCR9 on plasmacytoid DCs (pDCs) defines a tolerogenic subpopu-
lation [26]. We therefore compared the distribution of DC subsets in
CCR9
2/2 and WT animals at steady state and during DSS colitis.
We first confirmed that a subset of pDCs from MLNs and
spleen of WT animals expresses high levels of CCR9 [26,27]
(Figure 5A and data not shown). Then, we analyzed distribution of
DC subpopulations in CCR9
2/2 and WT animals by assessing
the ratio between pDCs and conventional DCs (cDCs). According
to the literature [15], cDCs were gated based on expression of high
levels of CD11c and MHC II pDCs were defined as MHC II
low,
CD11c
low and PDCA-1
+ cells [28]. The relative distribution of
Figure 3. Exacerbation of DSS-mediated colitis in CCR9
2/2 mice. (A) Higher IBD scores during the recovery phase in CCR9
2/2 animals. WT
mice are depicted in gray circles (n=51), CCR9
2/2 mice in open circles (n=63). (B) Representative H&E sections from colons of WT and CCR9
2/2 mice
(d0, d13 and d17; 106-magnification). CCR9
2/2 intestinal mucosa displays exacerbated IBD symptoms. (C) Significant colon shortening in CCR9
2/2
mice (open circles) at d17. Colon length was measured from d0 to d17. ***P,0.005, n.s. not significant.
doi:10.1371/journal.pone.0016442.g003
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did not differ in lymphoid organs or large intestinal tissues at
steady state between the two strains (data not shown). In line with
the literature, our results showed an increase in the pDC/cDC
ratio in SPL and MLN due to an accumulation of pDCs in
CCR9
2/2 mice (Figure 5B). The pDC/cDC ratio in the colon of
both strains was comparable.
We next analyzed the effects of DSS colitis on the distribution of
pDCs in MLNs and observed a biphasic pattern. At d10, a drop in
pDC numbers was detected in WT and CCR9
2/2 mice. Then,
we observed an accumulation of pDCs, which was significantly
more pronounced in CCR9
2/2 when compared to WT animals
(2-fold at d13, 4-fold at d17, Figure 5C). The enhanced
accumulation of pDCs observed in CCR9
2/2 animals signifi-
cantly shifted the pDC/cDC ratio in MLNs at d13 and d17. The
relative distribution of cDCs and their subsets during DSS colitis
was comparable in both strains (Figure S4 and S5). The pDC/
cDC ratio in the colon (Figure 5E) and in the SPL (Figure S6) was
not affected.
Since the severity of colitis symptoms in mice is partly
dependent on the DSS dose [10,23], we hypothesized that a
higher dose of DSS might induce a comparable accumulation of
pDCs in MLNs of WT animals. Administration of 4% DSS indeed
induced accumulation of pDCs when compared to 2% DSS
(Figure 5C and 5D). We detected a pDC subset that expresses
CCR9. The majority of accumulating pDCs, however, were
lacking CCR9 expression (Figure 5D), implying that these pDCs
have an inflammatory rather than a tolerizing immune phenotype
[26].
We compared maturation/activation levels of the accumulating
pDCs by comparing MHC II, CD80 and CD86 expression levels.
Low expression levels of CD11b on WT and CCR9
2/2 pDCs
(Figure 6A, left) confirmed that these cells were different from the
activated macrophages described in Figure 4. By gating on the
CD11b
low PDCA-1
+ population, we confirmed that the pDCs
were MHC II
+ (Figure 6A, right) and CD11c
low and Ly6C
high
(data not shown). Comparative analysis of expression levels of
MHC II, CD80 and CD86 showed that these surface markers
were upregulated in pDCs from CCR9
2/2 animals (Figure 6B).
Despite the different activation level, pDCs isolated from MLNs of
WT and CCR9
2/2 animals at d17 showed the same plasmacytoid
morphology (Figure 6C). In summary, these data show that
activated pDCs accumulate in the gut-associated lymphoid tissue
of CCR9
2/2 animals.
Discussion
The results presented in this study identify a novel role of
CCL25/CCR9 interactions in the pathogenesis of a well-
established acute colitis model mediated by oral administration
of DSS. In our study, DSS specifically targets the large intestine,
but not the small intestine, and we show that CCL25 expression is
upregulated after acute large intestinal inflammation. When
studying CCR9
2/2 mice with the DSS model, we found that
the large intestinal mucosa displays characteristics of enhanced
tissue inflammation resulting in exacerbated IBD symptoms and a
delay in recovery from tissue injury. Thus, our findings are of high
relevance for clinical care of human IBD as they point to potential
detrimental effects of CCR9-blocking therapy for patients suffering
from inflammation in the large intestine, as commonly observed in
ulcerative colitis. This suggests that blocking CCL25/CCR9
interactions in ulcerative colitis patients may lead to an inefficiency
in resolving intestinal inflammation or, at worst case, even
exacerbated IBD symptoms. An oral CCR9 antagonist
(CCX282-B) is currently used in a Phase II clinical trial for the
treatment of Crohn’s disease and has shown efficacy in the
treatment of patients with moderate to severe small bowel Crohn’s
disease [8]. This compound has shown potent inhibition of
CCL25-mediated chemotaxis of CCR9-expressing cells [29].
However, contradicting results have emerged in the role of
CCL25/CCR9 interactions in the experimental small intestinal
inflammation of the TNF
Dare mouse model that mimics human
Crohn’s Disease. Walters et al. showed that the orally bioavailable
CCR9 antagonist CCX282-B can ameliorate, in one single
experiment, the severity of small intestinal chronic inflammation
of TNF
Dare mice [29]. Apostolaki et al. demonstrated that the
development of intestinal inflammation in the TNF
Dare mouse
model is critically dependent on b7 integrin-mediated T-
lymphocyte recruitment, while the function of the CCL25/
CCR9 axis in T-cell specific mucosal recruitment appears
dispensable in this model [30]. The fact that Walters et al. did
not provide the CCR9 antagonist orally but subcutaneously may
explain such discrepancy. Oral administration of CCR9 antago-
nists should thus be evaluated in animal models of large intestinal
inflammation.
In the SAMP1/Yit chronic ileitis mouse model that shares
similarities with the TNF
Dare mouse model, Matsuzaki et al.
showed that antibodies against the a4b7-integrin ligand
MAdCAM-1 significantly inhibited adhesion of T lymphocytes
to microvessels of the terminal ileum of SAMP1/Yit mice, and
led to a strong chronic ileitis suppressive effect [31]. Although
antibody blockade of CCL25/CCR9 interactions ameliorated
early, but not late, SAMP1/Yit chronic murine ileitis [32], it
would be very interesting to test whether the CCR9 antagonist
CCX282-B and/or CCR9-deficiency in the SAMP1/Yit ileitis
model can ameliorate small intestinal chronic inflammation as
well. The fact that these studies were focused on small intestinal
but not large intestinal inflammation, made CCL25 and CCR9
attractive candidates for the treatment of Crohn’s disease but
not ulcerative colitis. However, prior to this study, no work
has been presented on CCL25/CCR9 interactions in an
experimental acute colitis mouse model mediated by DSS
exposure.
Figure 4. The gastrointestinal tract of CCR9
2/2 animals shows multiple signs of exacerbated tissue inflammation. (A) Accumulation of
inflammatory macrophages. Flow cytometry analysis of MLNs of WT and CCR9
2/2 animals. Frequencies of inflammatory macrophages were
determined in MLN suspensions with anti-CD11c, CD11b, F4/80, Ly6C and MHC-II (in black) overlaid on isotype control mAbs (in gray). Data represent
the mean (+/2 SD) of 3 independent experiments of 3–5 pooled mice per genotype. (B and C) mRNA profiling of large intestinal tissues. Total RNA
was prepared from the colon of WT and CCR9
2/2 mice at d0 and d17 and was analyzed with the nCounter
TM system (mean +/2 SD of 3–5 animals
per group of 2 independent experiments). (B) Macrophage accumulation is reflected by increased mRNA levels of CD64 and Arginase1. (C)
Comparison of tissue immunophenotype of the large intestinal mucosa before and after DSS-mediated colitis in WT and CCR9
2/2 animals. (D and E)
T cell re-stimulation assay for cytokine production. (D) Representative cytometry bead array assay for Th1/Th2/Th17 cytokines. (E) Production of
TNFa, IFNc, IL-2, IL-6 and IL-17A is upregulated while production of IL-10 and IL-4 is down-regulated in T cells from CCR9
2/2 animals. Quantification
of cytokine production from WT (gray bars) and CCR9
2/2 cells (open bars). Data represent one experiment out of 3 independent experiments,
performed in triplicate (mean +/2 SD) of 3 pooled WT MLN and 3 pooled CCR9
2/2 MLN cell suspensions reactivated in vitro with anti-CD3e/anti-
CD28 mAbs for 72 h.
doi:10.1371/journal.pone.0016442.g004
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support the findings of Stenstad et al. showing expression of this
chemokine in the colon [33]. To date, only low expression levels
a ts t e a d ys t a t ew e r ed e s c r i b e d .W es h o wh e r et h a ti n f l a m m a t i o n
increases CCL25 expression in the large intestinal mucosa. It has
been described that the small intestinal mucosa reacts to
injection of the inflammatory cytokine TNFa with rapid
upregulation of CCL25 [34]. Our data suggest that the colonic
mucosa reacts similarly to inflammation, presumably to attract
CCR9-positive leukocytes to participate in the mucosal immune
response.
The most compelling argument for a physiologic role of
CCL25/CCR9 interactions during an inflammatory response in
the colon is derived from the increased susceptibility to colitis and
the high mortality rate observed in CCR9
2/2 animals. Increased
IBD scores, more pronounced weight loss, a delay in recovery
from acute inflammation and the inability to regain initial body
weight during the experimental time period support the critical
role for CCL25/CCR9 dependent trafficking events during the
acute and recovery phase of DSS colitis. The altered microenvi-
ronment of the large intestine appears to favor CCL25/CCR9-
independent migration of pro-inflammatory leukocytes in
Figure 5. CCR9
2/2 mice show altered ratios of dendritic cell subpopulations at steady state and during DSS-mediated colitis. (A)W T
MLNs contain CCR9
+ and CCR9
2 pDCs gated as MHC II
int and PDCA-1
high (left dot plot). CCR9 expression in WT pDCs (black line, right histogram) is
overlaid on CCR9
2/2 pDCs (in gray, right histogram) (B) Steady state distribution of pDCs and cDCs is altered in SPL and MLN of CCR9
2/2 mice. No
significant difference between strains is observed in the colon. cDCs were defined as CD11c
high and MHC II
high cells by flow cytometry. Ratio of
subpopulations is expressed on the y-axis as pDC/cDC cells. Data represent the mean +/2 SD of 4 independent experiments of 3–5 pooled mice per
group. (C) Accumulation of pDCs in MLNs of CCR9
2/2 animals. Percentages of pDCs in WT and CCR9
2/2 MLN are depicted in bold from d0 to d17 of
DSS colitis. (D) Accumulation of pDCs correlates with the level of tissue damage. Increase of DSS concentration to 4% augments the number of
CCR9
low/2 B220
+ PDCA-1
+ MHC II
int/high cells in MLNs of WT animals. (E) DSS-mediated tissue inflammation alters pDC/cDC ratios in MLN of CCR9
2/2
animals. Data points correspond to individual experiments corresponding to 17 DSS colitis experiments harvested at different time point using 3–5
pooled mice per genotype.
doi:10.1371/journal.pone.0016442.g005
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2/2 animals. This situation is highly relevant for our
understanding of the therapeutic effects of CCR9-antagonists as
this type of medication could result in a comparable scenario in
human IBD patients.
To date, targeting of chemokine receptors such as CCR2,
CCR5, CCR6, CXCR3, CXCR4 and CX3CR1 by gene
disruption or antagonistic peptides has been found to protect
animals from DSS colitis [35,36,37,38,39]. The mechanism
commonly proposed is that interference with chemokine receptor
function is beneficial, because these receptors are potentially pro-
inflammatory. In contrast, we show that CCR9
2/2 and CCL25
2/
2 animals respond with exacerbated IBD symptoms. To our
knowledge, this is the first report to show that interference with a
chemokine/receptor pair aggravates IBD symptoms. As a
mechanism, we propose that CCL25/CCR9 interactions are
critical components of an anti-inflammatory tissue response in the
colon.
The interpretation of our results as a consequence of an
impaired anti-inflammatory response in CCR9
2/2 animal is
supported by our data in two ways: the pronounced accumulation
of activated inflammatory macrophages and the increased
expression of the pro-inflammatory cytokines IL-1b, IL-6, and
TNF-a in the large intestinal mucosa. Expression of the latter
cytokines is not only described for animal models of colitis [40,41]
but also for human IBD [42,43], underlining the relevance of the
murine model for human disease. Unlike other models of murine
colitis [44], our model shows that the absence of CCR9 does not
change the immune profile of the inflammatory response. Only
higher levels of Th1- and Th17-type inflammatory cytokines, but
no Th2-type immune responses, were detected. Additionally, high
levels of IL-17A and IL-17F were detected as part of the
aggravated immunophenotype of CCR9
2/2 mice both at the
mRNA level and the protein level. As IL-17 is considerably
increased in chronic IBD patients [45], it is conceivable that the
CCL25/CCR9 interactions are playing a physiological role during
the development of the chronic disease symptoms as well. Melgar
et al. showed that a single cycle of high-dose DSS can induce
chronic inflammation over time in wild type C57Bl/6 mice [24].
Along this line, we have preliminary evidence that a single cycle of
low-dose DSS is sufficient in CCR9
2/2 C57Bl/6 animals to
induce chronic IBD (data not shown). Further investigation will
determine whether CCL25/CCR9 interactions play a role in DSS
chronic colitis.
The delayed recovery from acute colitis is further characterized
by an accumulation of pDCs and a change of the pDC/cDC ratio
in the gut-associated lymphoid tissue in CCR9
2/2 mice. pDCs
have been described as immune suppressive APCs [46] that can
induce systemic tolerance to T cell-mediated delayed-type
hypersensitivity after oral sensitization [47]. pDCs are also
discussed as regulators of DSS colitis [48]. However, Hadeiba et
al. described a significant difference in the ability of pDCs subsets
to promote tolerance [26]. In fact, CCR9 expression delineates a
tolerogenic pDC subset while CCR9-negative pDCs were unable
to prevent T cell activation/proliferation. Our results also suggest
the concerted action of two functionally distinct pDCs subsets: a
CCR9-positive tolerogenic pDC subset that regulates the inflam-
matory response during and after DSS colitis and a CCR9-
negative predominantly inflammatory pDC subset. When regula-
tory pDCs lose CCR9 expression due to genetic manipulation,
they also lose their ability to migrate in response to CCL25
upregulation in the colon and become trapped in the MLN.
Alternatively, CCR9 expression by itself could influence the
tolerogenic potential of these pDCs. One might even argue that
the subset of CCR9-positive regulatory pDCs is underrated in WT
animals, as these cells are likely to escape detection by flow
cytometry once they have reached large intestinal LP. These cells
likely down-regulate their surface chemokine receptors in response
to CCL25. The CCR9-negative pDCs appear inflammatory in our
model as demonstrated by the correlation of exacerbated IBD
symptoms with the expansion of this pDC subset. In CCR9
2/2
mice, the altered microenvironment might also favor CCL25/
CCR9-independent tissue homing of inflammatory pDCs. Addi-
tionally, the impaired balance of DCs subpopulations may
contribute to the enhanced activation of the immune system and
the failure to recover from tissue injury in the absence of
physiological CCL25/CCR9 interactions. It now will be impor-
tant to study if the impaired ratio of inflammatory and regulatory
pDCs, the expanded macrophage population or both cell types
regulate the exacerbated IBD symptoms in CCR9
2/2 animals.
The question whether this phenotype is actually exacerbated IBD
or rather an impaired ability to recover from acute large intestinal
inflammation also requires further analysis.
Figure 6. pDCs from CCR9
2/2 MLNs are more activated than WT pDCs. (A) pDCs of WT and CCR9
2/2 mice express low levels of CD11b in
contrast to inflammatory macrophages. pDCs were defined as CD11b
low MHC II
int/high PDCA-1
+.( B) CCR9
2/2 pDCs show signs of phenotypic
maturation. Maturation levels were assessed by comparing expression levels of MHC II and costimulatory molecules CD80 and CD86. (C) Morphology
of pDCs isolated from WT and CCR9
2/2 animals.
doi:10.1371/journal.pone.0016442.g006
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high CD4+ T cell transfer colitis
model in immuno-compromised animals can be achieved by
cotransferring Regulatory T cells (Tregs) [49]. Given the fact that
CCR9-expressing pDCs are inducers of T regulatory cell
functions, further examination of Tregs distribution and function
would determine whether Tregs play a role in DSS colitis recovery
and whether or not it is CCL25/CCR9 dependent.
In summary, our study shows that impairment of CCL25/
CCR9-interaction has profound negative effects on the regulation
of the local inflammatory immune response. While a phase II
clinical study with a CCR9-inhibitor suggests a therapeutic benefit
for Crohn’s disease patients [8], our results strongly suggest that
this form of therapeutic intervention could have detrimental effects
when offered to patients that suffer from ulcerative large intestinal-
specific inflammation.
Supporting Information
Figure S1 CCL25
2/2 mice show increased susceptibil-
ity to DSS colitis comparable to CCR9
2/2 animals. (A)A
mortality rate of 38% was observed in CCL25
2/2 (blue circles)
mice exposed to DSS for 7 days and 10 days of water when
compared to control CCL25
2/2 mice exposed to water only
(black circles). Data represent survival of 5 mice per group in 5
independent experiments; P value=0.0166 (Log-rank Test). (B)
Delayed recovery in CCL25
2/2 mice is evidenced by significant
weight loss and inability to recover to initial body weight. Body
weight was monitored daily and is expressed as percent of body
weight measured at d0. Data are displayed as the mean +/2 SD of
the mean of 5 independent experiments, each with 5 mice per
group. Blue circles show CCL25
2/2 mice exposed to DSS colitis,
black circles CCL25 control mice.
(TIF)
Figure S2 CCL25 mRNA expression increases during
the recovery phase of DSS-mediated colitis in WT
intestinal mucosa but not CCR9
2/2 large intestinal
mucosa. Y-axis shows expression CCL25 levels normalized to
b-actin mRNA. Data represent the mean +/2 SD; d10, n=3;
d13, n=5; d17, n=5; where n corresponds to the number of
experiments of 3 to 5 pooled large intestinal samples.
(TIF)
Figure S3 Cellularity in SPL and MLN of WT and
CCR9
2/2 animals during DSS colitis is comparable.
Collagenase digestion of SPL and MLN was performed at
indicated time points. Cell suspensions were counted with a
CasyH automatic cell counter. Each data point represents a single
mouse, WT mice are depicted in gray circles and CCR9
2/2 mice
are depicted in open circles. Horizontal black bars represent the
mean of SPL and MLN cell numbers from d0 to d17. SPL: spleen,
MLN: mesenteric lymph nodes.
(TIF)
Figure S4 Distribution of pDCs and cDCs in WT and
CCR9
2/2 mice during DSS colitis. Cell suspensions were
prepared from WT and CCR9
2/2 SPL, MLN and colonic
mucosa and were analyzed by flow cytometry. Frequencies of
pDCs (PDCA-1
+ MHC II
int/high) and cDCs (CD11c
high MHC
II
high) were determined and are graphed as percentages of total
leukocytes. Each data point represents a single animal. WT mice
are depicted as gray circles and CCR9
2/2 mice as open circles.
Horizontal black bars represent the mean of pDCs and cDCs
frequencies determined by flow cytometry from d0 to d17.
(TIF)
Figure S5 Flow cytometry analysis of cDCs subsets in
WT and CCR9
2/2 animals at d17 of DSS colitis. Cell
suspensions from SPL, MLN and colonic mucosa were analyzed
by flow cytometry. Frequencies of cDCs subsets (CD11c
high MHC
II
high) were determined and subsets were further analyzed based
on expression of CD11b and CD103. Percentages of cDCs subsets
are expressed as percentage of total cDCs and numbers are shown
in red in each graph. Dot plots are representative of 5 independent
experiments. We did not observe any statistically significant
differences in the frequencies of all cDC subsets analyzed.
(TIF)
Figure S6 Ratio of DC subsets in the spleen of CCR9
2/2
animals compares to WT spleens during DSS colitis.
Quantification of pDC/cDC ratios at d0, d7, d10, d13 and d17 in
WT (gray circles, left graph) and CCR9
2/2 mice (open circles,
right graph) by flow cytometry using a lineage negative staining to
remove any CD3
+, CD19
+ and CD11b
high cells. Each data point
corresponds to one experiment using 3–5 pooled animals.
Horizontal black bars represent the mean of pDC/cDC ratios
from d0 to d17.
(TIF)
Table S1 IBD scoring. Values represent the mean 6 SEM of
IBD scores depicted in Figure 3a.
(DOC)
Table S2 Colon Length. Values represent the mean 6 SEM
of colon length depicted in Figure 3c.
(DOC)
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